Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 華潤 醫藥 集團 有限公司 China Resources Pharmaceutical Group Limited ( Incorporated in Hong Kong with limited liability ) ( Stock Code : 3320 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board ( the " Board " ) of directors ( the “ Directors ” ) of China Resources Pharmaceutical Group Limited ( the “ Company ” or “ China Resources Pharmaceutical ” ) is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries ( the “ Group ” ) for the six months ended 30 June 2021 ( the " Reporting Period ” ) , together with the comparative figures for the previous year / period as follows : INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS For the six months ended 30 June 2021 REVENUE Cost of sales GROSS PROFIT Other income Other gains and losses Selling and distribution expenses Administrative expenses Other expenses Finance income Finance costs Finance costs , net 1 Six months ended 30 June 2021 2020 ( Unaudited ) ( Unaudited ) Notes HK $ ' 000 HK $ ' 000 114,487,606 89,387,142 ( 97,022,535 ) ( 74,520,320 ) 17,465,071 14,866,822 5 713,267 655,358 6 ( 298,070 ) ( 471,184 ) ( 8,282,999 ) ( 6,769,705 ) ( 2,701,117 ) ( 2,148,185 ) ( 671,025 ) ( 497,728 ) 270,200 333,599 ( 1,472,035 ) ( 1,554,707 ) 7 ( 1,201,835 ) ( 1,221,108 )